Please note that during the registration/re-registration procedure, a specialised expert evaluation is carried out of the primary materials submitted as part of the registration dossier for a medicinal product, in accordance with the requirements of Annexes 5 and 15 to the Procedure for the expert evaluation of registration materials for medicinal products submitted for state registration (re-registration), as well as the expert evaluation of materials on amendments to registration materials during the validity period of the registration certificate, approved by MoH order of 23 July 2015 No. 460 (hereinafter referred to as MoH order No. 460).
During the specialized expert evaluation of the registration dossier materials for the purpose of obtaining complete data on the efficacy, safety and quality of a medicinal product, each of the Center's expert commissions may twice request from the applicant the necessary materials supplementing the data on the efficacy, safety and quality of the medicinal product, with reference to the numbers of sections, subsections, clauses, subclauses and paragraphs of the Procedure; new requests for materials already reviewed by the expert shall not be allowed, except in cases where the additional materials have been provided incompletely.
If, within 90 working days after the Center's request for additional materials, the applicant does not send these materials or does not justify another deadline for providing the materials, or provides them incompletely, except for a certified copy of the document confirming that the manufacturing conditions of the medicinal product comply with the requirements for the manufacture of medicinal products in Ukraine (good manufacturing practice), the registration materials shall be withdrawn from review, of which the Center shall notify the applicant in writing within three working days.
If the applicant/representative of the applicant has submitted (or has not submitted) a letter(s) on the provision of an Addendum to the clinical data review and/or Risk management plan as part of the registration dossier materials, in view of the above, these documents should not be submitted as revised/additional materials.
If an Addendum to the clinical data review and/or Risk management plan is received as part of revised/additional materials, such documents will not be considered and, accordingly, their specialized expert evaluation will not be carried out.
In terms of fulfilling the obligations, the applicant must submit these documents after completion of the medicinal product re-registration procedure by declaring changes in the manner prescribed by law.»